Tachykinin receptors antagonism for asthma: a systematic review
Open Access
- 2 August 2011
- journal article
- review article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 11 (1) , 1-7
Abstract
Tachykinins substance P, neurokinin A and neurokinin B seem to account for asthma pathophysiology by mediating neurogenic inflammation and several aspects of lung mechanics. These neuropeptides act mainly by their receptors NK1, NK2 and NK3, respectively which may be targets for new asthma therapy. This review systematically examines randomized controlled trials evaluating the effect of tachykinins receptors antagonism on asthma. Symptoms, airway inflammation, lung function and airway inflammation were considered as outcomes. We searched the Cochrane Airways Group Specialized Register of Asthma Trials, Cochrane Database of Systematic Reviews, MEDLINE/PubMed and EMBASE. The search is as current as June 2010. Quality rating of included studies followed the Cochrane Collaboration and GRADE Profiler approaches. However, data were not pooled together due to different measures among the studies. Our systematic review showed the potential of NK receptor antagonist to decrease airway responsiveness and to improve lung function. However, effects on airway inflammation and asthma symptoms were poorly or not described. The limited available evidence suggests that tachykinin receptors antagonists may decrease airway responsiveness and improve lung function in patients with asthma. Further large randomized trials are still required.Keywords
This publication has 18 references indexed in Scilit:
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmaticsTherapeutic Advances in Respiratory Disease, 2009
- The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthmaPharmacology & Therapeutics, 2009
- Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous diseaseThe Lancet, 2008
- Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthmaPulmonary Pharmacology & Therapeutics, 2006
- Neurokinin3 receptor regulation of the airwaysVascular Pharmacology, 2006
- Overview of the Primary Structure, Tissue-Distribution, and Functions of Tachykinins and their ReceptorsCurrent Drug Targets, 2006
- Involvement of Tachykinin NK1 Receptor in the Development of Allergen-induced Airway Hyperreactivity and Airway Inflammation in Conscious, Unrestrained Guinea PigsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- The Effect of Inhaled FK224, a Tachykinin NK-1 and NK-2 Receptor Antagonist, on Neurokinin A-Induced Bronchoconstriction in AsthmaticsAmerican Journal of Respiratory and Critical Care Medicine, 1996